CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
1α-D3 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02993302
NCT02993302Phase 2Completed
CompareCT.gov

Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients

Dr Cipto Mangunkusumo General Hospital·interventional·Posted Dec 15, 2016·Updated Mar 4, 2020

In Brief

A Phase 2 clinical trial evaluating 1α-D3 and Placebos for Graves Disease. Completed, enrolled 25 participants.

Detailed Summary

Maturity level of dendritic cells (DC) plays a pivotal role in initiating and regulating autoimmunity. In Graves' disease (GD), DCs have more active immune responses than those in healthy subjects. Our previous study demonstrated immunoregulatory effects of in vitro 1,25-D3 on maturation of DC in GD patients. This study aims to evaluate the effect of oral 1α-D3 on DC maturation in GD patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraves Disease
Countries--
CollaboratorsIndonesia University

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 15, 2016
Enrollment StartJul 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.5 years ago

Interventions

1α-D3drug

patients were given PTU and 1α-D3

Placebosdrug

patients were given PTU and placebos